Minimal Residual Disease Testing for Cancer

Effective August 1, 2024, the medical criteria used to determine medical necessity for the following tests will be simplified: Guardant Reveal and Guardant Response. For additional details related this policy, please click here. 

Gene Expression Profiling for Cutaneous Melanoma

Effective July 1, 2024, prior authorization is being removed from CPT code 0089U for Medicare Advantage plans and commercial products. The service is being changed to a covered service. For additional details related to this policy, please click here.    

Miscellaneous Vascular Embolization Procedures 

Effective August 1, 2024, hemorrhoidal embolization (HydroPearl microspheres) will not be covered for Medicare Advantage plans and not medically necessary for commercial products. For additional details related this policy, please click here.